Gravid health status, medication use, and risk of neuroblastoma

American Journal of Epidemiology

Volumn 143, Issue 10, 1996, Pages 996-1001

  Michalek, Arthur M ^a   Buck, Germaine M ^b   Nasca, Philip C ^c   Freedman, Andrew N ^a   Baptiste, Mark S ^d   Mahoney, Martin C ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

case control studies; child; hormones; neoplasms; neuroblastoma

Indexed keywords

SEX HORMONE; VITAMIN;

ADOLESCENT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; FEMALE; FITNESS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MATERNAL DISEASE; NEUROBLASTOMA; PRENATAL DRUG EXPOSURE; PRESCHOOL CHILD; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; VITAMIN INTAKE;

EID: 0030005901     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a008682     Document Type: Article

References (19)

1. SPSS for Windows, Release 6.0. Chicago, IL: SPSS, Inc., 1993.
2. Levy E, Cohen A, Fraser FC. Hormone treatment during pregnancy and congenital heart defects. (Letter). Lancet 1973; 1:611.
3. Nora JJ, Nora AH. Birth defects and oral contraceptives. (Letter). Lancet 1973;1:941-2.
4. Janerich DT, Dugan JM, Standfast SJ, et al. Congenital heart disease and prenatal exposure to exogenous sex hormones. Br Med J 1977;1:1360-1.
5. Czeizel A, Toth J, Erodi E. Aetiological studies of hypospadias in Hungary. Hum Hered 1979;29(3):166-71.
6. Monteleone Neto R, Castilla EE, Paz JE, et al. Hypospadias: an epidemiological study in Latin America. Am J Med Genet 1981;10:5-19.
7. Calzolari E, Contiero MR, Roncarati E, et al. Aetiological factors in hypospadias. J Med Genet 1986;23:333-7.
8. IARC monographs on the evaluation of carcinogenic risks to humans, suppl 7. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1-42. Lyon: IARC, 1987.
9. Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science 1990;249:1007-11.
10. Moolgavkar SH. Hormones and multistage carcinogenesis. Cancer Surv 1986;5:635-48.
11. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284: 878-81.
12. Kramer S, Ward E, Meadows AT, et al. Medical and drug risk factors associated with neuroblastoma: a case-control study. JNCI 1987;78:797-804.
13. Schwartzbaum JA. Influence of mother's prenatal drug consumption on risk of neuroblastoma in the child. Am J Epidemiol 1992;135:1358-67.
14. Mandel M, Toren A, Rechavi G, et al. Hormonal treatment in pregnancy: a possible risk factor for neuroblastoma. Med Pediatr Oncol 1994;23:133-5.
15. Kushner BH, Helson L. Monozygotic siblings discordant for neuroblastoma: etiologic implications. J Pediatr 1985; 107: 405-9.
16. Klemetti A, Saxén L. Prospective versus retrospective approach in the search of environmental causes of malformations. Am J Public Health 1967;57:2071-5.
17. Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986;123:670-6.
18. Mulinare J, Cordero JF, Erickson JD, et al. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988;260:3141-5.
19. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-7.